Treatment-Resistant Depression: A Psychiatry Perspective on Pathophysiological Mechanisms, Biomarkers, and Novel Therapeutic Frontiers
Muhammad Bilal Akram, Ali Sher, Areena Fatima, Ayesha Arif, Dua Fozan Sareshwala, Zahra Nawaz, Umair Khalil
INNOVAPATH June 22, 2026 Peer reviewed DOI: 10.63501/54mphj57 via OpenAlex
Summary
Treatment-resistant depression (TRD) is a significant challenge for patients with major depressive disorder who do not achieve remission despite treatment. It is influenced by various neurobiological, inflammatory, and psychosocial factors. New insights into mechanisms like neuroinflammation and synaptic dysfunction have led to potential biomarkers and innovative therapies, including rapid-acting antidepressants and psychedelic-assisted therapy. These advancements could help create more personalized treatment strategies for TRD.
Study at a glance
| Population | patients with major depressive disorder experiencing treatment-resistant depression |
|---|---|
| Key finding | Emerging evidence indicates that TRD is a heterogeneous condition influenced by complex interactions among various factors, and new therapeutic strategies are being developed to address it. |
Abstract
Treatment-resistant depression (TRD) represents a major clinical and public health challenge, affecting a substantial proportion of patients with major depressive disorder who fail to achieve remission despite adequate pharmacotherapy. Emerging evidence suggests that TRD is a heterogeneous condition driven by complex interactions among neurobiological, inflammatory, and psychosocial factors. Advances in understanding pathophysiological mechanisms—including neuroinflammation, synaptic dysfunction, and neuroendocrine dysregulation—have facilitated the identification of potential biomarkers and the development of novel therapeutic strategies. This perspective explores current insights into the mechanisms underlying TRD, highlights promising biomarkers for diagnosis and treatment stratification, and discusses emerging therapeutic frontiers such as rapid-acting antidepressants, neuromodulation, and psychedelic-assisted therapy. Integrating these advances into clinical practice may enable a more personalized and effective approach to managing TRD.